Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study

Londoño, María Carlota; Garcı́a-Buey, Luisa; Mallolas, Josép; Barril, Guillermina; Ahumada, Adriana; Riveiro‐Barciela, Mar; Muñoz‐Gómez, Raquel; Roget, Mercè; Serra, M.Á.; Devesa, M. J.; Navascués, C.A.; Baliellas, Carme; Aldámiz‐Echevarría, Teresa; Gutiérrez, María Luisa; Tomás, Inmaculada; Polo-Lorduy, Benjamín; Bonet, Lucía; García‐Samaniego, J.; Jiménez, M; Prieto, M. A.; Moran, S.; Castro, Ana de; Delgado, María Antonieta; Gea, Francisco; Martín-Granizo, Ignacio; Montes, Marisa; Morano, Luís; Castaño, Manuel; Santos, Ignacio; Laguno, Montse; Losa, Juan Emilio; Montero, Marta; Rivero, A.; Manzanares, Amanda; Álvaro, Cristina de

doi:10.1016/s0168-8278(17)31920-7

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major novelty of the present study lies in the strong association observed between lack of SVR and identification of HCC soon after concluding DAA. Overall, the rates of SVR and virologic failure in our cohort (97.6% and 1.8%, respectively) were comparable with what has been observed in registration trials [38][39][40] and in real-life cohorts [25,41,42] . While some authors affirmed in several retrospective studies that DAA increased the rate of early recurrence/occurrence of HCC, the short follow-up, the small number of patients, and the study design did not allow definite conclusions [3,43,44] .…”

Section: Multivariate Analysis Of Factors Associated With De Novo Hccsupporting

confidence: 88%

Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment

Burlone¹,

Fangazio²,

Croce³

et al. 2020

View full text Add to dashboard Cite

Aim: Patients with chronic hepatitis C virus (HCV) infection who develop hepatocellular carcinoma (HCC) soon after treatment with direct antiviral agents (DAA) may have been harboring hitherto hidden tumors. If this were true, they should have a lower sustained viral response (SVR) rate, since active HCC hampers DAA efficacy. We aimed to verify this hypothesis. Methods: We included all patients who attended an HCV clinic, provided that they: (1) had no previous history of HCC; (2) had received at least one DAA dose; and (3) had been followed-up clinically and ultrasonographically for at least six months after concluding DAA. Results: The study population included n = 789 patients (55% males, median age 62 years). A median of 9.3 months (8.8-11.9) after concluding DAA, n = 19 (2.4%) patients were discovered to harbor HCC. In comparison to all others, patients with HCC were more commonly male (84% vs. 54%, P = 0.009), obese (47% vs. 17%, P = 0.002), and cirrhotic (95% vs. 35%, P < 0.001) and had less commonly achieved an SVR (68% vs. 98%, P < 0.001). Moreover, they had a trend for being less commonly treatment naïve (58% vs. 67%, P = 0.051). Based on multivariate analysis, the independent predictors of HCC were male sex (P = 0.031), cirrhosis (P = 0.004), obesity (P = 0.006), and failure to achieve an SVR (P < 0.001). Conclusion: Lack of achieving SVR is a strong independent predictor of development of HCC early after treatment of hepatitis C with DAA. Treatment failure should further alert clinicians to the possibility of this dreadful complication.

show abstract

Section: Multivariate Analysis Of Factors Associated With De Novo Hccsupporting

confidence: 88%

Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment

Burlone¹,

Fangazio²,

Croce³

et al. 2020

View full text Add to dashboard Cite

show abstract

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study

Cited by 1 publication

References 0 publications

Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment

Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment

Contact Info

Product

Resources

About